Galenika-Fitofarmacija a.d. Sustainability Profile
Galenika-Fitofarmacija a.d., commonly referred to as Galenika, is a prominent pharmaceutical company headquartered in Serbia (RS). Established in 1945, it has evolved into a key player in the pharmaceutical industry, focusing on the development, production, and distribution of a wide range of medicinal products. With a strong presence in both domestic and international markets, Galenika is renowned for its commitment to quality and innovation. The company offers a diverse portfolio of products, including prescription medications, over-the-counter drugs, and dietary supplements, distinguished by their adherence to rigorous quality standards. Galenika's strategic initiatives and significant investments in research and development have solidified its market position, making it a trusted name in healthcare. With a legacy of excellence, Galenika continues to contribute to the well-being of patients across various therapeutic areas.
DitchCarbon Score
How does Galenika-Fitofarmacija a.d.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Salt and Mineral Mining industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Galenika-Fitofarmacija a.d.'s score of 9 is lower than 93% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Galenika-Fitofarmacija a.d.'s reported carbon emissions
Galenika-Fitofarmacija a.d., headquartered in RS, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. Furthermore, there are no documented reduction targets or climate pledges associated with the company. As a current subsidiary, Galenika-Fitofarmacija a.d. may inherit climate-related commitments from its parent organization; however, no specific details regarding such commitments or initiatives have been provided. The lack of emissions data and reduction initiatives suggests that the company may still be in the early stages of developing a comprehensive climate strategy. In the broader context of the pharmaceutical industry, companies are increasingly focusing on sustainability and carbon reduction, often setting science-based targets to align with global climate goals. Galenika-Fitofarmacija a.d. will need to establish clear emissions reporting and reduction strategies to remain competitive and meet stakeholder expectations in this evolving landscape.
How Carbon Intensive is Galenika-Fitofarmacija a.d.'s Industry?
How Carbon Intensive is Galenika-Fitofarmacija a.d.'s Location?
Galenika-Fitofarmacija a.d.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Galenika-Fitofarmacija a.d. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
